sever
acut
respiratori
syndrom
caus
substanti
morbid
mortal
epidem
mani
featur
human
diseas
duplic
balbc
mice
infect
mouseadapt
version
viru
develop
respiratori
diseas
high
morbid
mortal
show
sever
diseas
correl
slow
kinet
viru
clearanc
delay
activ
transit
respiratori
dendrit
cell
rdc
drain
lymph
node
dln
consequ
defici
virusspecif
cell
respons
defect
correct
mice
treat
liposom
contain
clodron
deplet
alveolar
macrophag
inhibitori
am
believ
prevent
develop
immun
respons
environment
antigen
allerg
respons
interact
lung
dendrit
cell
cell
inhibitori
effect
also
nullifi
mice
am
pretreat
poli
c
directli
activ
am
rdc
tolllik
receptor
adopt
transfer
activ
rest
bone
marrowderiv
dendrit
cell
bmdc
protect
mice
lethal
infect
result
may
relev
sar
human
also
character
prolong
viru
persist
delay
develop
sarscovspecif
immun
respons
individu
sever
diseas
lung
expos
mani
challeng
environment
pathogen
defens
portal
must
tightli
regul
appropri
immun
respons
pathogen
mount
respons
innocu
antigen
minim
alveolar
macrophag
play
central
role
maintain
immunolog
homeostasi
lung
resid
am
continu
encount
inhal
substanc
due
expos
posit
alveolar
lumen
kept
quiescent
state
function
poorli
accessori
cell
vitro
cell
activ
mani
situat
activ
suppress
induct
adapt
immun
effect
alveolar
interstiti
dc
cell
vivo
elimin
alveolar
macrophag
use
clodronatefil
liposom
cl
lead
overt
inflammatori
reaction
otherwis
harmless
particul
solubl
antigen
alveolar
macrophag
adher
close
alveolar
epitheli
cell
aec
alveolar
wall
separ
distanc
mm
rdc
macrophagedeplet
mice
dc
enhanc
antigenpres
function
estim
pool
murin
alveolar
macrophag
process
intratrach
inject
bacteria
spillov
bacteria
dc
adapt
immun
induc
although
import
mechan
control
undesir
respons
inert
environment
antigen
selfevid
also
axiomat
countermeasur
must
avail
allow
revers
inhibit
challeng
inhal
pathogen
notabl
microbi
antigen
infect
respiratori
pathogen
influenza
viru
antigen
acquir
respiratori
dendrit
cell
rdc
cell
must
suffici
activ
overcom
antiinflammatori
factor
lung
rdc
migrat
lung
drain
lymph
node
dln
initi
antivir
cell
respons
interact
naiv
cell
antigenbear
dc
like
cell
undergo
activ
divis
dln
migrat
lung
elimin
virusinfect
cell
lead
resolut
infect
recent
secondari
peripher
interact
cell
antigenbear
rdc
lung
found
import
effect
antivir
immun
overal
rdc
activ
prerequisit
initi
mainten
immun
respons
patient
sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscov
develop
mild
fatal
pulmonari
diseas
mortal
incid
patient
wors
outcom
gener
exhibit
protract
clinic
cours
character
develop
adult
respiratori
distress
syndrom
ard
well
lymphopenia
neutrophilia
prolong
cytokin
product
viru
could
detect
nasopharyng
aspir
fece
long
day
diseas
onset
delay
viru
clearanc
may
result
suboptim
b
cell
respons
suboptim
neutral
antibodi
respons
detect
patient
sever
diseas
numer
studi
demonstr
sarscov
infect
fail
activ
macrophag
dendrit
cell
although
cell
infect
function
impair
antivir
cytokin
type
interferon
express
endocyt
capac
antigen
captur
compromis
review
unusu
find
rais
possibl
initi
infect
viru
result
delay
suboptim
activ
innat
immun
system
ineffici
activ
rdc
might
unabl
counter
potent
antiinflammatori
factor
normal
present
lung
result
defici
cell
respons
delay
kinet
viru
clearanc
recent
rodentadapt
strain
sarscov
caus
mild
fatal
respiratori
diseas
develop
sever
laboratori
demonstr
lethal
diseas
mice
infect
mouseadapt
strain
sarscov
prevent
am
antiinflammatori
properti
deplet
lung
prior
infect
treatment
tolllik
receptor
tlr
agonist
activ
rdc
transfer
activ
bone
marrowderiv
dendrit
cell
bmdc
also
prevent
lethal
outcom
togeth
result
demonstr
sarscov
ineffici
activ
immun
system
use
novel
mechan
evad
immun
recognit
deplet
inocul
protect
balbc
mice
lethal
infect
sarscov
infect
result
ineffici
activ
macrophag
dc
vitro
slow
viru
clearanc
prolong
clinic
cours
human
similarli
infect
vitro
result
upregul
fig
gate
shown
fig
determin
whether
inhibitori
am
play
role
sever
lung
diseas
deplet
cell
intranas
administr
clodron
liposom
cl
cl
use
deplet
lesser
extent
alveolarairway
dc
intranas
administr
affect
level
circul
macrophag
control
treat
mice
pb
describ
previous
balbc
mice
treat
ml
cl
pb
intranas
total
lung
cell
harvest
enzymat
digest
h
decreas
am
siglec
f
lung
frequenc
absolut
number
cellslung
cl
pbstreat
mice
fig
b
h
approxim
am
lung
deplet
fig
b
determin
whether
chang
clinic
diseas
deplet
balbc
mice
treat
ml
cl
infect
pfu
viru
mice
monitor
daili
weight
loss
mortal
viru
dosag
control
mice
lost
bodi
weight
die
fig
gener
day
day
post
infect
pi
deplet
inocul
day
day
complet
protect
mice
lethal
infect
anim
rapidli
regain
bodi
weight
fig
deplet
day
pi
protect
may
result
sever
diseas
observ
also
influenza
virusinfect
mice
note
week
old
mice
resist
infect
treatment
day
clodron
effect
clinic
cours
mice
data
shown
clodron
treatment
result
enhanc
kinet
viru
clearanc
viru
clear
treat
control
balbc
mice
day
pi
fig
b
next
examin
lung
section
chang
histolog
histolog
differ
lung
cltreat
control
mice
day
indic
deplet
am
result
signific
inflammatori
cell
recruit
lung
day
pi
pbstreat
mice
develop
rapidli
progress
interstiti
pneumonia
extens
edema
damag
bronchiolar
alveolar
epitheli
cell
fig
c
inflammatori
infiltr
consist
identifi
day
pi
cltreat
mice
much
better
outcom
less
destruct
pulmonari
architectur
extens
alveolar
interstiti
perivascular
inflammatori
cell
infiltr
fig
c
day
day
total
lung
cell
number
shown
fig
clodron
treatment
remov
also
alter
inflammatori
milieu
lung
consequ
level
proinflammatori
cytokin
chemokin
increas
within
hour
cl
pb
treatment
prior
viru
infect
day
pi
level
cytokin
gener
similar
cl
pbstreat
mice
consist
notion
delay
possibl
dysregul
immun
respons
contribut
sever
diseas
control
mice
tabl
infect
respiratori
virus
influenza
viru
respiratori
syncyti
viru
rsv
result
recruit
mhc
ii
dc
lung
unlik
infect
recruit
inflammatori
cell
includ
dc
lung
impair
mice
fig
total
lung
cell
number
increas
slightli
appreci
chang
number
respiratori
dendrit
cell
rdc
control
mice
clodron
treatment
result
enhanc
inflammatori
cell
recruit
lung
fig
c
nearli
tenfold
increas
number
rdc
within
day
fig
experi
distinguish
two
popul
rdc
alveolar
airway
dendrit
cell
adc
mhc
ii
interstiti
dendrit
cell
idc
mhc
ii
use
gate
strategi
shown
fig
day
pi
frequenc
mhc
ii
high
mhc
ii
high
adc
idc
sever
acut
respiratori
syndrom
sar
occur
human
popul
caus
novel
coronaviru
cov
human
sar
character
prolong
viru
excret
lymphopenia
delay
adapt
immun
respons
patient
sever
diseas
recent
small
anim
model
develop
mimic
featur
human
diseas
specif
balbc
mice
infect
mouseadapt
sarscov
develop
sever
respiratori
diseas
show
cell
respons
defect
mice
result
ineffici
activ
initi
immun
respons
viru
defect
correct
sever
treatment
includ
deplet
inhibitori
macrophag
lung
direct
activ
respiratori
dendrit
cell
import
initi
immun
respons
transfer
activ
dendrit
cell
prior
infect
modal
result
improv
initi
immun
respons
enhanc
antiviru
cell
respons
ineffici
activ
immun
respons
may
play
role
human
sar
result
suggest
possibl
strategi
might
use
develop
novel
antivir
therapi
increas
significantli
drugtreat
mice
modestli
idc
adc
pbstreat
mice
next
day
adc
idc
remain
activ
cltreat
mice
mostli
return
baselin
state
control
mice
fig
b
c
concomit
recruit
activ
rdc
also
observ
enhanc
rdc
migrat
drain
lymph
node
dln
use
track
method
rdc
label
lung
inocul
carboxyfluorescein
diacet
succinimidyl
ester
cfse
see
materi
method
fig
b
gate
mice
rdc
migrat
dln
peak
h
pi
migrat
acceler
treatment
clodron
hour
frequenc
number
cfse
rdc
dln
decreas
suggest
first
h
pi
import
period
rdc
migrat
also
twothre
fold
increas
total
cell
number
dln
fig
collect
result
show
dc
remain
activ
longer
time
lung
exhibit
enhanc
migrat
dln
cl
treatment
consequ
increas
number
rdc
frequenc
activ
fold
increas
total
activ
dc
lung
sinc
enhanc
rdc
migrat
dln
predict
result
enhanc
virusspecif
cell
respons
next
examin
magnitud
total
cell
respons
lung
cl
treat
control
infect
mice
clodron
treatment
result
greater
number
activ
cell
lung
fig
b
compar
pb
treatment
determin
clone
express
latter
upregul
activ
effector
cell
assess
effect
cell
respons
initi
identifi
set
restrict
virusspecif
cell
epitop
use
lung
deriv
cell
harvest
infect
mice
peptid
librari
cover
four
structur
protein
n
e
sarscov
sever
ifnc
induc
epitop
spike
nucleocapsid
n
protein
identifi
manuscript
prepar
epitop
describ
previous
epitop
newli
discov
note
previous
describ
restrict
cell
epitop
recogn
lungderiv
cell
assay
previou
report
identifi
cell
epitop
use
adenoviru
vector
dna
construct
express
singl
sarscov
protein
isol
peptid
specul
number
cell
recogn
previous
describ
epitop
present
low
level
infect
mice
compar
immunodomin
epitop
identifi
possibl
differ
antigen
present
infect
immun
mice
use
epitop
found
amdeplet
mice
exhibit
earlier
robust
virusspecif
cell
respons
measur
intracellular
cytokin
stain
ic
ifnc
wherea
control
mice
almost
virusspecif
cell
respons
day
pi
fig
b
pbstreat
mice
surviv
day
pi
mount
virusspecif
cell
respons
lung
level
much
less
observ
cltreat
mice
confirm
cell
function
use
vivo
cytotox
assay
splenocyt
costain
cfse
puls
cell
peptid
adopt
transfer
mice
h
harvest
total
lung
cell
robust
cell
cytotox
respons
observ
amdeplet
mice
kill
virusspecif
target
comparison
target
cell
lyse
control
mice
fig
c
result
thu
far
suggest
inhibitori
macrophag
domin
lung
support
transient
slightli
activ
measur
express
infect
fig
consid
marker
macrophag
matur
phagocytosi
present
lower
level
am
harvest
uninfect
mice
compar
macrophag
isol
site
eg
periton
macrophag
fig
upregul
infect
fig
surfac
level
import
maintain
lung
homeostasi
higher
periton
macrophag
fig
significantli
downregul
infect
fig
indic
am
continu
inhibitori
even
onset
infect
number
frequenc
am
increas
day
return
baselin
day
pi
control
mice
expect
remain
low
throughout
infect
clodron
treatment
fig
b
matur
rest
am
abl
suppress
vitro
prolifer
homolog
tcell
freshli
isol
rdc
poor
antigenpres
cell
consist
suppress
state
confirm
inhibitori
properti
am
isol
adc
total
lung
cell
cultur
vitro
h
presenc
absenc
am
cultur
absenc
am
adc
upregul
express
mhc
ii
cocultur
am
prevent
mhc
class
ii
lesser
extent
upregul
fig
c
prolong
presenc
am
lung
suggest
am
inhibit
rdc
activ
therebi
delay
dc
migrat
lung
lymph
node
also
inhibit
function
antiviru
cell
lung
examin
possibl
cocultur
am
cell
vitro
concanavalin
con
solubl
antibodi
treatment
lung
cell
result
prolifer
cell
measur
cfse
dilut
prolifer
almost
complet
inhibit
cocultur
purifi
am
ratio
fig
note
endog
am
remov
lung
cell
prepar
incub
tissu
cultur
plate
h
deplet
measur
flow
cytometri
absenc
prior
incub
robust
prolifer
observ
assess
effect
virusspecif
cell
isol
cell
cltreat
mous
lung
day
pi
use
microbead
stain
cfse
cell
stimul
hour
lung
cell
splenocyt
puls
three
cell
peptid
without
am
although
cell
prolifer
cell
clearli
detect
cocultur
am
cell
prolifer
total
inhibit
fig
e
thu
am
inhibit
nonspecif
specif
cell
prolifer
howev
cocultur
vitro
inhibit
ifnc
express
stimul
peptid
fig
consist
previou
data
show
am
inhibit
secret
con
astimul
cell
am
cell
separ
transwel
cocultur
signific
decreas
prolifer
observ
measur
cfse
dilut
fig
b
suggest
inhibit
cell
prolifer
requir
direct
cell
contact
poli
c
treatment
protect
mice
lethal
infect
result
describ
rais
possibl
direct
activ
rdc
lung
adopt
transfer
activ
dc
lung
would
bypass
inhibitori
function
signal
tolllik
receptor
tlr
result
seri
signal
event
lead
induct
acut
inflammatori
respons
ligand
bind
tlr
also
result
dendrit
cell
matur
necessari
initi
adapt
immun
respons
previou
report
show
poli
c
cpg
treatment
protect
anim
lethal
viru
infect
mechan
protect
investig
studi
preliminari
experi
treat
mice
ligand
sever
tlr
includ
poli
c
lp
cpg
pam
pam
observ
treatment
poli
c
fig
lesser
extent
cpg
data
shown
tlr
ligand
protect
mice
lethal
diseas
consequ
addit
analys
perform
treatment
poli
c
control
lp
sinc
wide
use
stimul
macrophag
dc
poli
c
mgmous
treat
mice
lost
origin
weight
quickli
recov
within
day
lpstreat
group
mgmous
lost
weight
death
occur
mice
within
day
viru
titer
higher
day
lung
mice
compar
mice
treat
poli
c
fig
b
poli
c
much
less
extent
lp
treatment
result
enhanc
upregul
am
fig
c
rdc
fig
treatment
tlr
agonist
result
modest
increas
small
decreas
express
fig
c
consist
result
obtain
clodron
treatment
fig
poli
c
treatment
result
earlier
robust
antigenspecif
cell
respons
observ
pb
fig
lpstreat
mice
fig
e
nearli
twenti
fold
cell
detect
lung
poli
c
treat
mice
compar
lp
recipi
day
pi
cell
function
vivo
kill
assay
fig
e
f
determin
whether
poli
c
lp
directli
activ
am
am
isol
stimul
vitro
agonist
h
stimul
poli
c
lp
treatment
result
pronounc
upregul
fig
treatment
poli
c
lp
partial
revers
abil
inhibit
cell
prolifer
stimul
con
fig
b
result
indic
poli
c
abrog
inhibitori
function
vivo
vitro
directli
activ
am
rdc
given
result
direct
deliveri
activ
dc
lung
might
overcom
ammedi
inhibit
activ
dc
exhibit
enhanc
abil
migrat
dln
stimul
cell
prolifer
ifnc
express
sinc
am
unabl
inhibit
costimulatori
molecul
express
previous
activ
dc
fig
next
assess
whether
adopt
transfer
activ
dc
could
bypass
inhibit
protect
mice
lethal
infect
purpos
bone
marrow
cell
harvest
mice
dc
select
cultur
treatment
gmcsf
plu
day
bmdc
activ
either
lp
poli
c
result
enhanc
mhc
class
ii
express
bmdc
fig
b
expect
unabl
activ
cell
activ
rest
bmdc
transfer
mice
h
prior
infect
mice
receiv
bmdc
activ
either
poli
c
lp
protect
fatal
outcom
although
still
lost
bodi
weight
mark
contrast
recipi
rest
bmdc
protect
fig
c
higher
viru
titer
detect
lung
day
mice
receiv
rest
bmdc
oppos
activ
bmdc
fig
bmdc
migrat
lung
dln
acceler
prior
activ
cfse
activ
bmdc
rest
bmdc
accumul
dln
recipi
mice
fig
b
addit
total
number
cell
dln
increas
dramat
activ
bmdc
transfer
fig
b
consist
enhanc
rdc
migrat
dln
recipi
activ
bmdc
develop
robust
cell
respons
lung
compar
receiv
rest
bmdc
fig
c
nearli
tenfold
cell
detect
lung
activ
bmdc
compar
rest
bmdc
recipi
day
pi
cell
function
vivo
kill
assay
fig
e
collect
result
indic
adopt
transfer
activ
bmdc
lung
amplifi
viru
specif
cell
respons
clear
viru
earlier
protect
mice
lethal
infect
pathogenesi
sar
patient
exhibit
sever
diseas
well
understood
includ
slow
viru
clearanc
prolong
clinic
cours
result
present
herein
suggest
sever
diseas
may
occur
part
infect
individu
mount
appropri
antiviru
cell
respons
antiviru
cell
critic
viru
clearanc
mice
infect
pathogen
influenza
viru
lcmv
unexpect
necessari
resolut
infect
sarscov
lymphopenia
associ
wors
prognosi
sar
patient
prior
studi
knowledg
shown
poor
prognosi
result
part
suboptim
cell
respons
defect
develop
protect
cell
respons
occur
viru
revers
antiinflammatori
state
natur
present
uninfect
lung
result
consist
vitro
studi
sarscov
abl
infect
activ
human
dc
macrophag
may
occur
part
coronavirus
includ
sarscov
invis
cellular
sensor
cell
type
alveolar
macrophag
play
central
role
maintain
immunolog
homeostasi
activ
suppress
induct
adapt
immun
effect
alveolar
interstiti
dc
cell
sever
molecul
includ
nitric
oxid
tgfb
implic
suppress
function
molecul
either
short
half
live
requir
celltocel
contact
consist
am
separ
distanc
mm
rdc
lung
result
also
suggest
cell
contact
close
proxim
target
cell
requir
am
unabl
suppress
cell
prolifer
separ
respond
transwel
membran
fig
b
anoth
mechan
maintain
antiinflammatori
state
lung
am
ingest
process
innocu
antigen
bacteria
reach
activ
rdc
deplet
result
enhanc
antigenpres
function
rdc
increas
abil
lyse
influenza
virusinfect
cell
report
indic
counter
quiescent
antiinflammatori
state
critic
develop
protect
immun
respons
result
indic
infect
sarscov
revers
quiescent
state
ineffici
use
three
approach
support
conclus
first
pretreat
mice
clodron
deplet
result
enhanc
activ
migrat
rdc
turn
led
develop
vigor
protect
virusspecif
cell
respons
lung
fig
activ
migrat
rdc
earli
time
pi
critic
time
initi
antisarscov
cell
respons
consist
treatment
clodron
day
pi
protect
fig
rdc
migrat
dln
larg
complet
hour
pi
fig
deplet
day
pi
result
sever
diseas
suggest
sarscovinfect
mice
virusspecif
cell
requir
addit
dc
stimul
lung
occur
influenza
ainfect
anim
second
activ
am
rdc
situ
via
treatment
tlr
agonist
also
circumv
antiinflammatori
state
lung
result
show
poli
c
agonist
lesser
extent
cpg
agonist
abl
perform
function
primarili
locat
plasmacytoid
dc
inabl
protect
mice
indic
activ
cell
insuffici
induc
protect
immun
respons
poli
c
activ
am
rdc
vivo
fig
c
vitro
fig
protect
anim
lethal
infect
abil
poli
c
stimul
rdc
activ
migrat
describ
previous
like
explain
protect
abil
note
poli
c
treatment
also
induc
type
ifn
express
lung
may
also
contribut
protect
effect
poli
c
like
major
effect
sarscov
modestli
sensit
ifn
treatment
cultur
cell
mice
addit
cl
treatment
induc
type
ifn
lung
show
ifn
induct
requir
protect
data
shown
lp
agonist
unabl
protect
mice
lethal
diseas
consid
possibl
lp
might
toxic
effect
unrel
bind
treatment
monophosphoryl
lipid
mpla
deriv
lp
agonist
less
toxic
also
protect
data
shown
result
consist
recent
studi
show
ligat
contribut
wors
outcom
sever
model
lung
injuri
ligat
absenc
treatment
specif
agonist
contribut
worsen
diseas
balbc
mice
sinc
infect
balbc
mice
result
signific
differ
clinic
diseas
compar
wild
type
balbc
mice
data
shown
third
show
adopt
transfer
activ
rest
bmdc
bypass
ammedi
suppress
protect
mice
lethal
diseas
fig
dc
matur
make
cell
potent
antigen
present
anim
also
result
loss
abil
take
antigen
howev
antigen
macropinocytosi
transient
stimul
activ
possibl
explain
transfer
bmdc
could
acquir
sarscov
antigen
present
cell
dln
altern
matur
dc
abl
uptak
antigen
crosspresent
activ
bmdc
preferenti
migrat
dln
fig
b
initi
protect
cell
respons
lung
fig
ce
transfer
success
inhibitori
am
revers
prior
rdc
activ
fig
three
experiment
intervent
result
enhanc
rdc
migrat
dln
enhanc
cell
respons
site
infect
lung
improv
outcom
notabl
virusspecif
cell
also
critic
viru
clearanc
mice
resist
infect
six
week
old
mice
defici
recombin
activ
enzym
activ
background
clear
viru
measur
day
even
day
pi
data
shown
yet
remain
complet
asymptomat
hand
mice
sever
combin
immunodefici
syndrom
scid
balbc
background
like
mice
genet
unabl
mount
cell
respons
develop
clinic
diseas
sever
observ
wild
type
balb
c
mice
scid
mice
succumb
infect
data
shown
compar
mortal
rate
balbc
mice
infect
dosag
viru
fig
collect
result
show
optim
cell
respons
requir
viru
clearanc
strainspecif
compon
initi
immun
respons
yet
defin
critic
prevent
clinic
diseas
resist
strain
outstand
question
sarscov
activ
am
rdc
balbc
mice
describ
sarscov
effici
activ
human
dc
macrophag
also
shown
effici
induc
costimulatori
molecul
upregul
murin
rdc
vivo
andor
vitro
fig
c
howev
virus
mechan
evad
host
recognit
sensor
still
effici
induc
immun
respons
exampl
success
resolut
influenza
viru
infect
requir
activ
immun
respons
via
rigi
nlr
nodlik
receptor
inflammasom
pathway
even
though
influenza
viru
encod
immuneevad
protein
hsv
lymphocyt
choriomening
viru
hepat
c
viru
rsv
human
cytomegaloviru
recogn
via
mechan
rsv
f
protein
activ
cell
via
mechan
virus
vaccinia
viru
directli
inhibit
tlr
express
confirm
import
molecul
viru
recognit
host
tlr
signal
also
import
sarscov
recognit
innat
immun
system
sinc
mice
resist
viru
becom
suscept
genet
delet
precis
tlr
receptor
requir
protect
mice
known
present
pathway
effici
induc
balbc
mice
infect
area
futur
investig
conclus
shown
lethal
diseas
mice
infect
mouseadapt
strain
sarscov
correl
lack
activ
am
rdc
lethal
diseas
prevent
am
antiinflammatori
properti
deplet
lung
prior
infect
deplet
result
enhanc
dc
recruit
lung
acceler
migrat
dln
vigor
antisarscov
cell
respons
treatment
tlr
agonist
activ
am
rdc
transfer
activ
bmdc
also
prevent
lethal
outcom
togeth
result
demonstr
sarscov
hide
immun
system
use
novel
mechan
evad
immun
recognit
mice
pathogenesi
sar
human
may
involv
similar
stealth
mechan
pathogenfre
balbc
mice
purchas
nation
cancer
institut
frederick
md
mice
maintain
anim
care
facil
univers
iowa
anim
studi
approv
univers
iowa
anim
care
use
committe
african
green
monkey
kidneyderiv
vero
cell
grown
dulbecco
modifi
eagl
medium
dmem
gibco
grand
island
ny
supplement
mm
hepe
fetal
bovin
serum
fb
atla
biolog
fort
collin
co
mouseadapt
sarscov
kind
gift
dr
kanta
subbarao
nih
bethesda
maryland
viru
passag
vero
cell
mice
lightli
anesthet
isofluran
infect
intranas
pfu
viru
ml
dmem
medium
mice
monitor
weight
loss
mortal
daili
work
viru
conduct
univers
iowa
biosafeti
level
laboratori
core
facil
obtain
lung
viru
titer
anim
sacrif
indic
time
point
postinfect
pi
lung
remov
phosphat
buffer
salin
pb
tissu
homogen
use
manual
homogen
titer
vero
cell
plaqu
assay
cell
fix
formaldehyd
stain
crystal
violet
three
day
postinfect
viral
titer
express
pfug
tissu
peptid
librari
cover
structur
protein
sarscov
provid
bei
resourc
manassa
va
virusspecif
peptid
synthes
biosynthesi
inc
lewisvil
tx
tlr
agonist
poli
c
monophosphoryl
lipid
mpla
cpg
imidazoquinolin
compound
pam
pam
purchas
invivogen
san
diego
ca
lp
purchas
alexi
biochem
farmingdal
ny
alveolar
macrophag
deplet
perform
treatment
liposom
contain
dichloromethylen
bisphosphon
clodron
clodron
gift
roch
diagnost
gmbh
mannheim
germani
encapsul
liposom
describ
earlier
indic
time
mice
anesthet
intraperiton
inject
avertin
administ
ml
clodron
liposom
pb
anim
anesthet
transcardi
perfus
pb
follow
zinc
formalin
lung
remov
fix
zinc
formalin
paraffin
embed
section
stain
hematoxylin
eosin
mice
anaesthet
ml
pentobarbit
mgml
lundbeck
inc
deerfield
il
indic
time
point
lung
vascular
bed
flush
via
right
ventricl
ml
pb
elimin
blood
lung
drain
lymph
node
remov
lung
cut
small
piec
digest
hbss
buffer
contain
fc
mm
hepe
mgml
collagenas
roch
indianapoli
mgml
dnase
roch
min
rt
lymph
node
minc
press
though
wire
screen
particul
matter
remov
mm
nylon
filter
obtain
singlecel
suspens
cell
enumer
trypan
blue
exclus
situ
cfse
stain
cfse
molecular
probe
eugen
dissolv
mm
dmso
store
use
cfse
stock
solut
dilut
dmem
media
concentr
mm
administ
mlmous
follow
anesthesia
isofluran
follow
monoclon
antibodi
use
studi
rat
antimous
rat
antimous
rat
antimous
rat
antimous
hamster
antimous
rat
antimous
rat
antimous
siglec
f
mous
antimous
ia
bd
bioscienc
san
diego
ca
rat
antimous
ifnc
antimous
rat
antimous
ebiosci
san
diego
ca
rat
antimous
biolegend
san
diego
ca
rat
antimous
serotec
raleigh
nc
surfac
stain
cell
block
mg
antibodi
rat
serum
stain
indic
antibodi
fix
use
cytofix
solut
bd
bioscienc
intracellular
cytokin
stain
ic
cell
cultur
per
h
indic
time
period
presenc
brefeldin
bd
bioscienc
cell
label
surfac
antibodi
fixedpermeabil
cytofix
cytoperm
solut
bd
bioscienc
label
antiifnc
antibodi
flow
cytometri
data
acquir
bd
facscalibur
lsr
ii
bd
bioscienc
flow
cytomet
cellquest
bd
bioscienc
analyz
use
flowjo
softwar
tree
star
inc
ash
vivo
cytotox
assay
perform
day
infect
previous
describ
briefli
splenocyt
naiv
mice
costain
sigmaaldrich
st
loui
mo
either
mm
nm
cfse
molecular
probe
eugen
label
cell
puls
indic
peptid
mm
h
cell
group
mix
togeth
cell
total
cell
transfer
mice
h
transfer
total
lung
cell
isol
target
cell
distinguish
host
cell
basi
stain
cfse
stain
gate
cell
percentag
kill
calcul
previous
describ
am
obtain
uninfect
lung
previous
describ
briefli
lung
inflat
warm
pb
contain
bsa
mm
lignocain
sigmaaldrich
st
loui
mo
via
cannul
trachea
lavag
least
time
cell
collect
centrifug
resuspend
rpmi
gibco
grand
island
ny
contain
fc
atlanta
lawrencevil
ga
cultur
h
use
presenc
absenc
stimul
demonstr
inhibit
polyclon
cell
prolifer
splenocyt
lung
cell
amdeplet
attach
plate
h
label
mm
cfse
ad
well
stimul
mgml
con
sigma
mg
ml
solubl
ebiosci
cultur
am
ratio
h
inhibit
virusspecif
cell
prolifer
lung
cell
purifi
amdeplet
anim
day
pi
use
microbead
miltenyi
biotec
cologn
germani
day
splenocyt
puls
mm
peptid
celldeplet
lung
cell
ad
apc
cultur
am
ratio
h
cell
harvest
stain
antibodi
subject
flow
cytometr
analysi
purif
lung
dc
adc
popul
purifi
lung
balbc
mice
fac
sort
base
express
mhc
ii
fig
enrich
puriti
bone
marrowderiv
dc
bmdc
gener
previous
describ
briefli
red
blood
celldeplet
bm
cell
plate
densiti
ml
rpmi
fetal
calf
serum
mm
hepe
mm
lglutamin
mm
gentamicin
sulfat
penicillinstreptomycin
mm
sodium
pyruv
mm
supplement
uml
recombin
granulocytemacrophag
coloni
stimul
factor
bd
pharmingen
uml
recombin
ebiosci
cell
incub
day
medium
replac
everi
day
day
bmdc
stimul
without
mgml
poli
c
mgml
lp
h
microbead
miltenyi
automac
magnet
cell
sorter
miltenyi
biotec
cologn
germani
use
purifi
dc
puriti
confirm
flow
cytometri
balbc
mice
lightli
anesthet
isofluran
bmdc
ml
pb
adopt
transfer
h
infect
student
test
use
analyz
differ
mean
valu
group
result
express
error
mean
sem
p
valu
consid
statist
signific
figur
gate
strategi
dc
gate
strategi
adc
idc
am
lung
harvest
digest
collagenas
examin
adc
idc
am
popul
flow
cytometri
gate
follow
marker
idc
mhc
ii
adc
mhc
ii
siglec
f
b
gate
strategi
migratori
dc
mice
treat
ml
mm
cfse
h
cfse
instil
singl
cell
suspens
prepar
lung
dln
gate
express
flow
cytometri
repres
side
scatter
versu
cfse
stain
gate
cell
shown
figur
cytokin
express
cell
cocultur
requir
direct
amt
cell
contact
inhibit
cell
prolifer
am
harvest
bronchoalveolar
lavag
fluid
balf
cultur
amdeplet
lung
cell
stimul
sarscov
peptid
h
presenc
absenc
am
brefeldin
ad
last
h
cocultur
ifnc
express
determin
intracellular
stain
data
repres
three
independ
experi
b
am
harvest
bal
fluid
cultur
well
dish
h
use
singl
cell
suspens
prepar
spleen
mice
stain
mm
cfse
stimul
either
mgml
con
mgml
solubl
antibodi
h
semimembran
subject
flow
cytometri
data
repres
two
independ
experi
tabl
bioplex
assay
cytokin
chemokin
product
infect
mice
treat
either
pb
cl
h
infect
lung
harvest
day
day
day
pi
homogen
ultraviolet
light
inactiv
sampl
analyz
cytokin
chemokin
express
use
bioplex
cytometr
bead
assay
luminex
luminomet
biorad
concentr
cytokin
chemockin
express
pgml
lung
homogen
p
valu
found
mb
doc
